Skip to main content
. 2020 Feb 11;15(2):e0228188. doi: 10.1371/journal.pone.0228188

Fig 2. Kaplan-Meier estimates of overall survival.

Fig 2

A) Overall survival among KRAS altered and tested KRAS negative patients with actionable alteration. B) Overall survival among ALK rearrangement and tested ALK rearrangement negative patients. C) Overall survival among broad-based panel tested and small-panel tested patients. D) Overall survival among actionable altered and wild-type patients. P values comparing risk groups were calculated with the log-rank test.